Latest news with #SunPharmaceuticalIndustriesLimited
The Hindu
19-06-2025
- The Hindu
Counterfeit cholesterol drugs worth ₹3 lakh seized in raids at Koti
Officials from the Drugs Control Administration (DCA) carried out raids on multiple pharmaceutical dealers in Koti, Hyderabad and uncovered counterfeit stocks of the cholesterol-lowering medications Rosuvas F 20 and Rosuvas F 10. These drugs are prescribed to lower cholesterol and triglyceride levels and prevent heart-related ailments. The spurious drugs were being circulated in the open market under the guise of legitimate products manufactured by Sun Pharmaceutical Industries Limited. During the inspections on Thursday, DCA's special enforcement team raided two outlets, Ganga Pharma Distributors and Sri Nandini Pharma, and seized fake batches of the medicine, both falsely labelled as being manufactured in December 2024 and set to expire in May 2027. The counterfeit packaging claimed Sun Pharma's Sikkim unit as the manufacturing site, said a release. The estimated value of the seized counterfeit medicines is ₹3 lakh. Upon verification, Sun Pharmaceutical Industries Limited confirmed to the authorities that the seized stocks were not genuine and had not been produced by their company. Officials stated that a detailed investigation is underway to trace the entire supply chain of the counterfeit products and that legal action will be initiated against all those found responsible.
Business Standard
14-06-2025
- Business
- Business Standard
Sun Pharma updates on US FDA inspection
At Halol FacilitySun Pharmaceutical Industries has informed that the US FDA conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries Limited's Halol facility (Gujarat, India) from 02 June to 13 June 2025. At the conclusion of the inspection, the US FDA issued a Form-483, with 8 by Capital Market - Live News
Business Upturn
14-06-2025
- Business
- Business Upturn
Sun Pharma's Halol facility receives form 483 with 8 observations from US FDA
By Aman Shukla Published on June 14, 2025, 09:42 IST Sun Pharmaceutical Industries Limited, one of India's leading pharmaceutical companies, has announced the conclusion of a recent inspection by the United States Food and Drug Administration (US FDA) at its Halol manufacturing facility located in Gujarat, India. The inspection was conducted from June 2 to June 13, 2025, as part of the regulatory authority's routine evaluation of current Good Manufacturing Practices (GMP) compliance. At the end of the inspection, the US FDA issued a Form 483 to the company, outlining eight observations. In a regulatory filing, Sun Pharma stated: 'We hereby inform that the US FDA conducted a GMP inspection of our Halol facility from 02 June to 13 June 2025. At the conclusion of the inspection, the US FDA issued a Form-483 with 8 observations.' A Form 483 is issued by the US FDA when its investigators observe any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related regulations. These observations are based on conditions found during routine inspections and are intended to prompt the company to take corrective actions. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
04-06-2025
- Business
- Business Upturn
SPARC shares drop nearly 20% after key drug trial fails
By Aman Shukla Published on June 4, 2025, 11:35 IST Shares of Sun Pharma Advanced Research Company (SPARC) declined sharply by nearly 20% after the company announced the discontinuation of clinical trials for its experimental drug Vibozilimod (SCD-044). The drop came following an update from Sun Pharmaceutical Industries Limited, SPARC's collaborator, which revealed that the Phase 2 trials for Vibozilimod failed to meet their primary efficacy endpoints. The drug, which was being tested for treating moderate-to-severe psoriasis and atopic dermatitis, did not show the required 75% improvement in PASI and EASI scores by Week 16. As a result, no further trials will be conducted, marking a significant setback for both companies' specialty drug pipelines. Shares of Sun Pharma Advanced Research Company (SPARC) opened at ₹185.00 and touched an intraday low of ₹156.14, reflecting a sharp decline. The stock did not move above its opening price, indicating bearish sentiment. SPARC is currently trading closer to its 52-week low of ₹109.30, far below the 52-week high of ₹258.00. As of 11:34 AM, the shares were trading 17.95% lower at Rs 160.15. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
